المؤلفون: Claire Bewshea, James R Goodhand, Peter Kelleher, Nick Powell, Rachel L Griffiths, Nicholas A. Kennedy, Philip J Smith, Shaji Sebastian, Arkir Zehra, Bessie Cipriano, Desmond Chee, Louise Greathead, Benjamin Hamilton, Simeng Lin, Rachel Nice, Lauranne A A P Derikx, Neil Chanchlani, Hajir Ibraheim, Peter M. Irving, Klaartje Kok, Charlie W. Lees, Jonathan Macdonald, Timothy J. McDonald, Allan Dunlop, Tariq Ahmad

المصدر: Journal of Crohn's and Colitis, 16, 3, pp. 389-397
Journal of Crohn's & Colitis
Journal of Crohn's and Colitis, 16, 389-397
Chanchlani, N, Lin, S, Chee, D, Hamilton, B, Nice, R, Arkir, Z, Bewshea, C, Cipriano, B, Derikx, L A A P, Dunlop, A, Greathead, L, Griffiths, R L, Ibraheim, H, Kelleher, P, Kok, K B, Lees, C W, MacDonald, J, Sebastian, S, Smith, P J, McDonald, T J, Irving, P M, Powell, N, Kennedy, N A, Goodhand, J R & Ahmad, T 2022, ' Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses : Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients ', Journal of Crohn's & colitis, vol. 16, no. 3, pp. 389-397 . https://doi.org/10.1093/ecco-jcc/jjab153Test

مصطلحات موضوعية: Male, TNF, Gastroenterology, Serology, Seroepidemiologic Studies, adalimumab, skin and connective tissue diseases, immunosuppression, biology, medicine.diagnostic_test, General Medicine, Eccojc/1020, Original Article, Drug Monitoring, Antibody, Life Sciences & Biomedicine, biologic, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], medicine.drug, vedolizumab, Adult, medicine.medical_specialty, Combination therapy, MATURATION, Vedolizumab, DEFICIENT, inflammatory bowel disease, Internal medicine, Adalimumab, medicine, Humans, Seroprevalence, AcademicSubjects/MED00260, Biological Products, Science & Technology, Gastroenterology & Hepatology, SARS-CoV-2, business.industry, COVID-19, 1103 Clinical Sciences, vaccination, Inflammatory Bowel Diseases, Infliximab, ALPHA, Therapeutic drug monitoring, CLARITY, Antibody Formation, biology.protein, Tumor Necrosis Factor Inhibitors, infliximab, business, INFLAMMATORY-BOWEL-DISEASE

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c08447d7329ab51228946a10f8ee899Test

المؤلفون: Langford, Thomas, Arkir, Zehra, Chalkidou, Anastasia, Goddard, Kate, Kaftantzi, Lamprini, Samaan, Mark, Irving, Peter

المصدر: JMIR Research Protocols

مصطلحات موضوعية: Crohn’s disease, medicine.medical_specialty, Cost effectiveness, therapeutic drug monitoring, Disease, Inflammatory bowel disease, 03 medical and health sciences, 0302 clinical medicine, Quality of life (healthcare), inflammatory bowel disease, Protocol, medicine, antidrug antibodies, 030212 general & internal medicine, Intensive care medicine, Protocol (science), Crohn's disease, medicine.diagnostic_test, business.industry, anti-TNF, General Medicine, medicine.disease, Infliximab, 3. Good health, Therapeutic drug monitoring, ELISA, 030211 gastroenterology & hepatology, infliximab, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fec5304268af32ac8b8dfcdbac0ca896Test
https://doi.org/10.2196/11218Test